一品红：己酮可可碱缓释片获注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of its drug, Ketoconazole Sustained-Release Tablets, which is indicated for peripheral vascular diseases, including intermittent claudication and rest pain [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has been granted the drug registration certificate [1] - The approved drug, Ketoconazole Sustained-Release Tablets, targets peripheral vascular diseases [1] - The specific indications for the drug include intermittent claudication and rest pain [1]